LEIDEN, Netherlands–(BUSINESS WIRE)–#Adults—Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation … [Read more…]
SINGAPORE–(BUSINESS WIRE)–#ClinicalTrials–Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer. Dr. Tharmaratnam brings nearly three decades of experience in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on … [Read more…]
BILLERICA, Mass.–(BUSINESS WIRE)–$BRKR #BRKR—Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the … [Read more…]
InduPro will leverage its proprietary platform to develop bi- and tri-specific therapeutics that discover rationally selected Tumor Associated Proximity Antigens (TAPAs) to pair as co-targets with Tumor Associated Antigens, in collaboration with Lilly SEATTLE & CAMBRIDGE, Mass.–(BUSINESS WIRE)–InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of … [Read more…]
Service expansions accelerate pharmacy’s achievement of 2 million shipments while maintaining industry-leading patient support MADISON, Wis.–(BUSINESS WIRE)–Lumicera Health Services, a leading specialty pharmacy solutions provider and Top 10 national specialty pharmacy, announced today the promotion of Ben Heiser, PharmD, to Senior Vice President and Chief Executive Officer (CEO). This follows a period of sustained expansion … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Stylus Medicine, Inc. (“Stylus”), a biotechnology company dedicated to developing transformative in vivo genetic medicines, today announced that Emile Nuwaysir, Ph.D., chairman and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:00 p.m. PT. About Stylus Medicine Stylus Medicine is developing transformative … [Read more…]
EDINBURGH, Scotland–(BUSINESS WIRE)–RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis … [Read more…]
MARSEILLE, France–(BUSINESS WIRE)–#immunotherapy–Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well … [Read more…]
Ad hoc announcement pursuant to Art. 53 LR GENEVA–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ: STAA) announced on August 5, 2025. “Throughout this process we remained disciplined with our views on price and risk. Moving … [Read more…]
PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to … [Read more…]
